Industry Leaders in Clinical Hemp Research

When you choose Ananda Professional, you’re buying much more than just a product. You’re helping support multiple clinical trials for CBD - the first of their kind. These studies are the missing link to gain FDA approval for CBD - a step that would bring regulation (and therefore certainty) to the CBD industry.

This will also elevate CBD and hemp into their rightful roles as powerful, safe, and effective alternative treatment options to mainstream medications.

We reinvest money from every purchase to advance clinical evidence for CBD - helping customers, farmers, and CBD companies alike.

Why Our Research is Vital

Natural icon

1. Clinical evidence is essential to gain FDA approval for CBD, allowing its use as a true medicinal substance

Natural icon

2. High-quality clinical trials verify the usefulness of CBD for various ailments, eliminating ‘snake-oil syndrome’

Natural icon

3. With the recent relegalization of CBD, studying it gives us insight to how it works

Natural icon

4. Completing this research means millions of people can use CBD for health conditions, forgoing more dangerous/addictive alternatives


Committed in research to advance the clinical evidence of hemp extract


Clinical trails to support the legitimacy of Ananda Professional Products


Quality control checks and highest lab testing standards in the hemp industry

Research Studies

Opioid Reduction

Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy with better safety profile

  • Study Focus: Opioid Reduction
  • Product Studied: Full Spectrum Softgels
  • Research Institution: Murphy Clinic
  • Patient Population: Chronic Opioid
  • Location: Louisville, KY
  • Type/Phase: Prospective Cohort Study
  • Status: Complete-Published 2019 in Journal Postgraduate Medicine
View Product

CIPN (Chemotherapy-Induced Peripheral Neuropathy)

The purpose of this study is to assess the effect of a hemp-based cannabidiol (CBD) product, Ananda Hemp Spectrum Gelcaps, on the severity and duration of chemotherapy-induced neuropathy (CIPN) among non-metastatic breast, colorectal, uterine and ovarian cancer patients who received neoadjuvant or adjuvant therapy that included neurotoxic chemotherapeutic agents.

  • Study Focus: CIPN (Chemotherapy-Induced Peripheral Neuropathy)
  • Product Studied: Full Spectrum Softgels
  • Research Institution: Lankenau Institue for Medical Research
  • Patient Population: Breast, colon, and ovarian cancer
  • Location: Philadelphia, PA
  • Type/Phase: Phase 2
  • Status: Enrollment underway (FDA authorized-IND)
View Product

Sleep and Anxiety

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to determine the efficacy of THC-free CBD oil in reducing the severity of agitation among participants, and determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

  • Study Focus: Sleep and Anxiety
  • Product Studied: THC free Softgels
  • Research Institution: Eastern Virginia Medical School
  • Patient Population: Dementia
  • Location: Norfolk, VA
  • Type/Phase: Phase 2
  • Status: Enrollment underway (FDA authorized-IND)
View Product


This trial involves participation in a randomized placebo-controlled clinical trial. The study also involves a placebo, which has no therapeutic value, but is similar in look, taste and smell to the other treatment being tested. The product that is being tested is a medicinal cannabis product, specifically cannabidiol or CBD. Recent research has identified that CBD can have benefits in improving sleep disturbance symptoms and mood.

  • Study Focus: Sleep
  • Product Studied: Full Spectrum Softgels
  • Research Institution: Southern Cross University
  • Patient Population: Healthy Population
  • Location: Australia (4 sites)
  • Type/Phase: Phase 2b
  • Status: Enrollment underway
View Product


This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with moderate alcohol use disorder according to the DSM-V. If eligible for the study, subjects will be randomized to receive one of the conditions for 8 weeks.

  • Study Focus: Addiction
  • Product Studied: Full Spectrum Softgels
  • Research Institution: University of Colorado
  • Patient Population: Alcohol Use Disorder
  • Location: Boulder, CO
  • Type/Phase: Phase 2
  • Status: Enrollment underway (FDA authorized-IND)
View Product

Pain (endometriosis)

The present study aims to fill the existing gaps in the literature by providing an a priori test of the interest, use patterns, and impact of CBD and cannabis use on pelvic pain, absenteeism, physical and psychosocial symptoms and functioning, and medication use. This is a naturalistic observational study where participants are assessed monthly over the course of one menstrual cycle (approximately 1 month).

  • Study Focus: Pain (endometriosis)
  • Product Studied: Endo Relief Cream
  • Research Institution: University of Newcastle
  • Patient Population: Endometriosis
  • Location: Newcastle, Australia
  • Type/Phase: Avatar Study
  • Status: Scheduled Completion 3Q22
View Product

Cognitive Decline

Coming soon

  • Study Focus: Cognitive Decline
  • Product Studied: Full Spectrum Softgels
  • Research Institution: University of Colorado
  • Patient Population: Adults, No Dementia
  • Location: Boulder, CO
  • Type/Phase: Phase 2
  • Status: Pending FDA Authorization-IND (expected 1Q22)
View Product

Our Research Partners

Inspired by Katelyn Lambert

Katelyn Lambert was diagnosed with Dravet Syndrome at the age of two in 2014. This life-changing event for our Chairman, Barry Lambert and his family, was only the beginning. shortly after Katelyn Lambert's seizures were under control, they set off a chain of events that would see their vision to research, educate and ultimately ensure all australians could access high-quality afforable CBD become a reality.